EA Policies for Single Patient
Exciva is currently developing an investigational product (EXV-802) for potential treatment for agitation in people with Alzheimer’s Disease. Exciva understands that there may be individuals who are interested in access to EXV-802 outside of a clinical trial. At this stage of development, the only way to gain access to EXV-802 is by participating in a clinical study.